These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10741290)

  • 1. A new standard of care for treatment of ovarian cancer.
    Piccart MJ; Du Bois A; Gore ME; Neijt JP; Pecorelli S; Pujade-Lauraine E
    Eur J Cancer; 2000 Jan; 36(1):10-2. PubMed ID: 10741290
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy for ovarian cancer--a consensus statement on standard practice.
    Adams M; Calvert AH; Carmichael J; Clark PI; Coleman RE; Earl HM; Gallagher CJ; Ganesan TS; Gore ME; Graham JD; Harper PG; Jayson GC; Kaye SB; Ledermann JA; Osborne RJ; Perren TJ; Poole CJ; Radford JA; Rustin GJ; Slevin ML; Smyth JF; Thomas H; Wilkinson PM
    Br J Cancer; 1998 Dec; 78(11):1404-6. PubMed ID: 9836470
    [No Abstract]   [Full Text] [Related]  

  • 3. ICON3 and chemotherapy for ovarian cancer.
    Ozols RF; Markman M; Thigpen JT
    Lancet; 2002 Dec 21-28; 360(9350):2086-7; author reply 2088. PubMed ID: 12504453
    [No Abstract]   [Full Text] [Related]  

  • 4. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 6. Good manners for the pharmaceutical industry.
    Perren T
    Lancet; 1997 Aug; 350(9074):370-1. PubMed ID: 9251669
    [No Abstract]   [Full Text] [Related]  

  • 7. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for ovarian cancer--trials, controversies and funding.
    Hawkins RE
    Br J Cancer; 1998 Dec; 78(11):1402-3. PubMed ID: 9836469
    [No Abstract]   [Full Text] [Related]  

  • 9. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

  • 10. First-line chemotherapy for ovarian cancer - the controversy continues.
    Kaye SB
    Br J Cancer; 2002 Oct; 87(8):813-4. PubMed ID: 12373592
    [No Abstract]   [Full Text] [Related]  

  • 11. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy of advanced ovarian cancer: current status and future directions.
    Ozols RF; Vermorken JB
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?
    Sugiyama T
    Int J Clin Oncol; 2006 Jun; 11(3):163. PubMed ID: 16850120
    [No Abstract]   [Full Text] [Related]  

  • 16. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it time for some new approaches for treating advanced ovarian cancer?
    McGuire WP
    J Natl Cancer Inst; 2006 Aug; 98(15):1024-6. PubMed ID: 16882933
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
    Markman M
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of intraperitoneal chemotherapy in ovarian cancer.
    Markman M
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.